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Abstract 
Background: Esophageal cancer (EC) is the eighth most common incident cancer 
and the sixth most common cause of cancer death. Chemoresisatnce is the main 
obstacle of EC at present. Increasing evidence has shown that microRNAs (miRNAs) 
play an important role in carcinogenesis and chemotherapy resistance of various 
cancers. However, it is unknown how miRNAs regulate chemoresistance of EC. We 
performed a series of assays to investigate the mechanisms of miRNAs in 
chemoresistance of EC. 
Methods: For this study, first 5-FU resistant cell models were established in four 
different esophageal cancer cell lines, then miRNAs levels were detected in 5-FU 
resistant esophageal cancer cells (5-FUres EC cells) as well as the original sensitive 
cancer cell lines by qPCR. After transfecting miR-221 mimics (miR-221), inhibitors 
(anti221) or negative control siRNA (siRCtrl) into parental EC cells and 5-FUres EC 
cells respectively, in vitro and in vivo experiments were performed in this study. In 
vitro, the cell proliferation and cytotoxicity of EC cells towards 5-FU were assessed 
by CCK-8.  In vivo, OE33 and OE33-5FUres cells were implanted subcutaneously in 
nude mice. The tumor sizes were measured at appropriate time. Ki67 and CD31 
expression for assessing proliferation and angiogenesis were detected in tumor by 
immunohistochemistry staining (IHC) and immunofluorescence staining (IF). To 
further investigate the molecular mechanisms of miR-221 in 5-FU resistance of EC 
cells, target genes of miR-221 were predicted using bioinformatics analysis, and were 
further analyzed by qPCR and Western blot. For identification of direct target 
relationship of miR-221 and DKK2, the luciferase reporter vectors pGL3-DKK2-wt 
and pGL3-DKK2-mut with wild type or mutant 3’UTR sequence of DKK2 were 
constructed, and luciferase reporter assay was conducted after co-transfecting miR-
221 mimics and luciferase reporter vectors. The distribution of β-catenin and activity 
of Wnt/β-catenin pathway were assessed using IF and TOP/FOP Flash reporter assay. 
For understanding why 5-FUres EC cells acquire mesenchymal cell- like morphology, 
EMT related markers E-cadherin and vimentin expression were detected by qPCR and 
Western blot. Published EMT related Wnt/β-catenin target genes were detected by 
customer RT-PCR profile.  
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Results: In this study, miR-221 was significantly up-regulated in all 5-FUres EC cells 
compared to the respective parental EC cells. In vitro, knockdown of miR-221 
suppressed cell proliferation and sensitized esophageal cancer cells to 5-FU at 2.5 
μg/ml and 20 μg/ml. In vivo, deregulation of miR-221 by its inhibitors suppressed 
xenograft tumor growth and also inhibited angiogenesis of tumors in BALB/c nu-nu 
mice. 120 common genes in four microRNA target prediction databases were 
predicted as candidate targets of miR-221. Here we focus on DKK2 an antagonist of 
Wnt/β-catenin pathway. The mRNA and protein expression of DKK2 was reversely 
associated with miR-221 expression in 5-FUres EC cells. Luciferase reporter analysis 
revealed that DKK2 was a direct target gene of miR-221 in EC cells. IF staining 
results showed that β-catenin was located in the cell membrane and cytoplasm of the 
original EC cells whereas in 5-FUres EC cells β-catenin was translocated into the 
nucleus. After transfection of miR-221 inhibitors in 5-FUres EC cells, β-catenin moved 
back to the cytoplasm and cell membrane. Moreover, TOP/FOP Flash reporter 
analysis indicated a dramatic decrease of luciferase activity by β-catenin siRNA and 
miR-221 inhibitors. These results suggested Wnt/β-catenin pathway was inactivated 
by β-catenin siRNA and miR-221 inhibitors.  In this study, acquisition of 
mesenchymal- like phenotype in 5-FUres EC cells is associated with EMT pathway, 
and some EMT related Wnt/β-catenin target genes including MYC, CDH1, CD44 and 
chemoresistance marker ABCG2 were found to be regulated by miR-221 in 5-FUres 
EC cells.  
Conclusion: miR-221 plays an important role in chemoresistance of EC via 
modulating Wnt-EMT pathway. miR-221 may serve as a prognosis marker and 
therapeutic target for patient with 5-FU resistant EC.  
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Introduction 
1. Esophageal cancer  
Esophageal cancer is the eighth most common incident cancer and the sixth most common 
cause of cancer death[1]. There are two main subtypes of esophageal cancer: squamous cell 
carcinoma and adenocarcinoma, which have quite distinct etiology and epidemiology[3,4]. 
Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer 
which occurs mainly in China, India, Iran and the south of Africa[1,7]. However esophageal 
adenocarcinoma (EAC) is more prevalent in European countries and the United States, which 
increases dramatically in incidence observed in the last twenty years[3,8]. Nowadays clinical 
treatment for esophageal cancer consists of surgery, chemotherapy and radiotherapy. The 
prognosis of patients who receive only surgery is poor with a 5-year survival rate ranging 
from 15% to 39%[9,10]. To improve the survival rate of patients with esophageal cancer, 
multimodal treatment, including chemotherapy plus surgery and chemoradiotherapy plus 
surgery, has been developed. Both cisplatin and 5-fluorouracil (5-FU) are the most common 
chemotherapy reagents used in esophageal cancer. However, the reported response rate to 
chemotherapy including 5-FU is very low which is only 19% to 40% and about half of these 
patients do not achieve a good response to chemotherapy[10,11]. Therefore, chemoresistance 
has become a major obstacle in the treatment of esophageal cancer.  
1.1  Definition of esophageal cancer  
Esophageal cancer is cancer arising from the esophagus which runs between throat and 
stomach. The cancer cells start in the inner layer mucosa and grow outward through the 
submucosa and the muscle layer.  It is divided into two main types: squamous cell carcinoma 
and adenocarcinoma. Esophageal squamous cell carcinoma (ESCC): the esophagus is 
normally lined with squamous cells. Cancer arising from these cells is called esophageal 
squamous cell carcinoma which is mainly present in the upper two-thirds of esophagus[12] 
(Fig I). Esophageal squamous cell carcinoma is similar to head and neck cancer in their 
appearance and association with tobacco and alcohol consumption[13]. Esophageal 
adenocarcinoma (EAC): adenocarcinoma starts in gland cells which replace an area of 
squamous cells as what happens in Barrett’s esophagus. It occurs mainly in the lower third of 
the esophagus (Fig I). Rare cancers: other types of cancer can also start in the esophagus, 
including lymphomas, melanomas, and sarcomas. But these cancers are rare and are not 
discussed further in this document.  
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Figure I. Esophageal cancer. It is divided into two main types: esophageal squamous cell 
carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC is mainly present in the 
upper two-thirds of esophagus, while EAC occurs mainly in the lower third of the esophagus. 
1.2  Chemotherapy and resistance of esophageal cancer 
Esophageal cancer, a malignant carcinoma, has high invasiveness and metastasis, as well as 
the poor prognosis. Currently the combination therapy with 5-FU and cisplatin is the standard 
and active regimen for esophageal cancer. Chemotherapy has been proved effective for 
improving survival and life quality of esophageal cancer patients. However chemotherapy 
fails to kill all cancer cells because of intrinsic or acquired drug resistance. Here we mainly 
investigate the mechanism of 5-FU therapy and resistance in cancer.  
 
Figure II. Structure of 5-FU. 
 
Esophageal squamous 
cell carcinoma 
Esophageal 
adenocarcinoma 
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5-Fluorouracil (5-FU) is an important anticancer drug, which has been used as the first-line 
drug in treatment of various types of malignances. However, nowadays 5-FU resistance 
during the curses of treatment has been common, which is an important cause of failure for 
esophageal cancer therapy. 5-FU is a heterocyclic aromatic organic compound which has a 
similar structure with that of the pyrimidine molecules of DNA and RNA[14]. It leads to 
cytotoxicity and cell death by interfering with nucleoside metabolism and is incorporated into 
RNA and DNA[15,16]. 5-FU exerts it anticancer function through several ways: (1) Inhibition 
of thymidylate synthase (TS). TS is an important enzyme for synthesis of the pyrimidine 
thymidine and DNA replication. It methylates deoxyuridine monophosphate (dUMP) to form 
thymidine monophosphate (dTMP). 5-FU blocks synthesis of the pyrimidine thymidine and 
DNA replication by interrupting the action of TS and then results into cell apoptosis and cell 
death. (2) Incorporation of its metabolites into RNA and DNA. The 5-FU metabolite FUTP is 
extensively incorporated into RNA, disrupting RNA processing and leading to profound 
effects on cellular metabolism and viability.  
Based on the above functional mechanism, dysregulation of TS, as an important cause of 5-
FU resistance, has been reported in varieties of cancer. Spears CP et al[17] found that TS level 
in 5-FU resistant colon tumors is higher than in nonresistant tumors; moreover the non-
resistant tumors show a decrease in total TS after pretreatment with 5-FU, in contrast the 
resistant tumors do not exhibit such decrease of pretreatment levels. Shibata J et al[18] found 
that an increase of TS transcription is related with the 5-FU resistance of colon cancer. Wang 
et al[19] reported that ectopic expression of TS protein is a key cause of 5-FU resistance of 
cancers.  
There are some other explainations of the mechanisms of 5-FU resistance, such as alterations 
in drug influx/efflux, enhancement of drug inactivation and activation of signal transduction 
pathways including Wnt/β-catenin pathway and EMT pathway.  
The superfamily of ATP-binding cassette (ABC) transporters, promiscuous transporters of 
both hydrophobic and hydrophilic compounds, function as active drug efflux pumps in cancer 
cells. It is reported that the overexpression of ABC transporters result in the reduction of 
cellular accumulation of drugs in cancer cells and lead to poor response of patients to 
chemotherapy[20]. Members of ABC transporters ABCB1 (P-glycoprotein, MDR1), ABCC1 
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(multidrug resistance associated protein 1, MRP1) and ABCG2 (breast cancer resistance 
protein, BCRP) are well known to be involved in the active extrusion of anticancer drugs 
from cells[21]. The emerging evidence indicates that the expression of ABCG2 is associated 
with a poor clinical response to chemotherapy[22–25]. Inhibition or down-regulation of ABCG2 
may be a valid approach to reverse ABCG2-mediated drug resistance and to improve the 
clinical efficacy of cancer chemotherapy.  
Wnt/β-catenin signaling pathway is also called the canonical Wnt pathway which plays a key 
role in controlling multiple tumor relevant aspects, such as cell fate specification, cell 
proliferation, and cell migration of cells[26]. Activation of this pathway is a major factor in 
carcinogenesis and in various cancers. Of interest is the observation that Wnt/β-catenin 
pathway is involved in the maintenance and self- renewal of caner stem cells, which is a key 
cause of resistance in cancer therapy[27]. In Wnt/β-catenin signaling pathway, Wnt binding to 
cell surface receptors of the Frizzled family (FZD), the adenomatous polyposis coli 
(APC)/Axin/CK1/GSK3β destruction complex function becomes disrupted [26]. β-catenin is 
stabilized and accumulated in the cytoplasm, and then translocated to the nucleus to interact 
with the TCF/LEF transcription factors[28]. Moreover, Wnt binding to a second receptor low-
density lipoprotein receptor-related proteins (LRP-5/6), also induces the activation of the 
Wnt/β-catenin signaling pathway[29]. The Dickkopf families bind to and repress LRP, 
inactivating this pathway as shown in Figure III [30].  
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Figure III. Wnt/β-catenin signaling pathway. In this canonical Wnt pathway, Wnt binding to 
cell surface receptors FZD and LRP leads to a release of DVL. The APC/Axin/CK1/GSK3β 
destruction complex function becomes disrupted. β-catenin is stabilized and accumulated in 
the cytoplasm, and then translocated to the nucleus to interact with the TCF/LEF transcription 
factors. However, the Dickkopf families bind to LRP and repress the interaction between LRP 
and Wnt, further inactivating the Wnt/β-catenin signaling pathway.  
In preliminary work, our group compared Wnt pathway related gene expression in side 
population cells of 5-FU sensitive and resistant esophageal cancer cells. We found a 
significant increase of β-catenin mRNA expression as well as ectopic expression of other 
related genes such as WNT5a, WNT11, CTNNB1, GSK-3 and TCF4 in side population 
cells[31]. It was found that the WNT signaling pathway participates in chemoresistance of 
several cancers like osteosarcoma[32], prostate cancer[33], ovarian cancers[34], 
neuroblastoma[27],  hepatocellular carcinoma[35], pancreatic cancer[36] and colorectal cancer 
stem cells[37]. If the Wnt/β-catenin signaling pathway is involved in chemoresistance of 
esophageal cancer cells will be evaluated in this work.  
Epithelial-mesenchymal transition (EMT) is a biologic process that allows a polarized 
epithelial cell, which normally interacts with the basement membrane via its basal surface, to 
undergo multiple biochemical changes that enable it to assume a mesenchymal phenotype [38]. 
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This process decreases intercellular contact and increases cellular mobility, which has also 
been recently implicated to provide cancer cells their migratory and invasiveness properties. 
More and more evidence suggests a direct link between EMT and self- renewal characteristics 
of stem cells.  This finding indicates that EMT plays a critical role in resistance to 
chemotherapy by controlling the self-renewal of cancer stem cells. A majority of studies 
suggest the association of EMT and chemoresistance in a variety of cancer cells[39]. Johji Hara 
et al. reported decreased expression of epithelial cell marker E-cadherin and increased 
expression of mesenchymal cell markers Snail, ZEB1 and N-cadherin in residual tumors after 
chemotherapy in human esophageal cancers, compared with chemo-naive tumors. Moreover, 
in patients with preoperative chemotherapy, the decreased expression of E-cadherin and 
increased expression of Snail in residual tumors are correlated significantly with poor 
response to chemotherapy and poor prognosis[39]. Grygielewicz P et al. found the resistant cell 
lines (SNU-16R) demonstrated changes characteristic of epithelial- to-mesenchymal transition 
(EMT)[40]. In the present study, the 5-FU resistant esophageal cancer cell lines acquired EMT 
characteristics. These findings suggest that cancer cells after chemotherapy switch to 
mesenchymal phenotype, resulting in chemoresistance and poor clinical outcome.  
2. MiRNAs and esophageal cancer 
MicroRNAs (miRNA) are a family of endogenous noncoding single strand small RNA which 
is approximately 19 nt-21 nt in length. Mature miRNAs could degrade mRNA or suppress the 
protein translation by directing RISC complex and binding to the 3’ untranslated region 
(3’UTR) of target mRNA[41]. miRNAs have been found to play an important regulatory role 
in cell proliferation, differentiation and apoptosis, as well as carcinogenesis[41]. Dysregulation 
of miRNAs has been found in a variety of cancers including esophageal cancer. Moreover, 
accumulating evidence indicates that miRNAs could also be involved in decreased sensitivity 
of cancer cells to chemotherapy, which has been an obstacle of anticancer treatment. 
Therefore, to better understand the function of miRNAs in the mechanisms of 
chemoresistance of esophageal cancer and target specific miRNAs will be helpful for 
anticancer therapy.  
2.1  MiRNAs and carcinogenesis of esophageal cancer 
To date, more and more studies have been reported that miRNAs are important for the 
development of esophageal cancer. Here we reviewed the characteristics of miRNAs which 
are relevant in carcinogenesis of esophageal cancer (Chart 1).  
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Some miRNAs play a role as oncomirs in the development of esophageal cancer. The level of 
miR-221 and miR-222 increases in esophageal cells exposed in bile acid and in EAC tissues  
versus BE tissues. And inhibitors of miR-221 and miR-222 can reduce EAC tumor growth by 
increasing the level of p27Kip1 and CDX2[2]. MiR-21 expression in serum and tumor tissue 
of patients with esophageal cancer is higher, and it can induce cell proliferation and invasion 
in esophageal cancer[42–45]. miR-192 can promote the progress of esophageal cancer[46]. The 
microRNAs, miR-31 and miR-375, are candidate markers in Barrett's esophageal 
carcinogenesis[47]. MicroRNA-100 promotes migration and invasion through mammalian 
target of rapamycin in esophageal squamous cell carcinoma[48].   
Some other miRNAs play a role as antagomirs in the development of esophageal cancer. The 
level of miR-27a decreases in esophageal squamous cell carcinoma and it functions as a 
tumor suppressor in esophageal squamous cell carcinoma by targeting KRAS[49,50]. Down-
regulation of miR-27a/b might reverse multidrug resistance of esophageal squamous cell 
carcinoma[51]. Compared to the normal adjacent tissues, let-7 expression is lower in ESCC 
tissues, and the lower expression is correlated with lymph-note metastasis of ESCC. In 
addition, let-7 can inhibit cell proliferation in ESCC cells[52]. MiR-203 and miR-205 
expression is lower in BE and EAC compared with the normal esophageal epithelium. 
Overexpression of miR-203 and miR-205 can suppress cell proliferation, cell invasion and 
migration in esophageal cancer cells by regulating different target genes expression[42,53,54]. 
The above findings suggest miRNAs play an important role in carcinogenesis of esophageal 
cancer by regulating oncogenes or suppressor genes.  
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Chart 1.  Summary of miRNAs associated with esophageal cancer  
Up-regulated miRNAs Down-regulated miRNAs 
Esophageal epithelial cell 
miR-21[55]  
miR-143/145[55] Let-7[52] 
miR-192[56] miR-203/205[55,56] 
miR-194[55]  
miR-215[55] 
miR-221/222[2] 
 
Barrett’s esophagus 
  
 Let-7[52] 
miR-21[43,44] miR-23a[57] 
miR-30[55] miR-27a/b[51] 
miR-143/145[55,58] miR-31[6,47] 
miR-192[55] miR-99a[57] 
miR-194[55] miR-100[57] 
miR-215[55] miR-125b[59] 
 miR-203/205[42,53,54] 
  
Esophageal adenocarcinoma 
 
2.2  MiRNAs and chemoresistance of esophageal cancer 
Accumulating evidence suggests that dysregulation of miRNAs in chemoresistant esophageal 
cancer is common. Furthermore several studies report that miRNAs modulate cytotoxicity and 
sensitivity of esophageal cancer to chemotherapy by regulating chemoresistance-related genes 
expression or signal transduction pathways. In table 1, we reviewed the miRNAs which are 
deregulated and are related to chemoresistance of esophageal cancer.  
Hsa-miR-141 is located on chromosome 12 and specifically expressed in human epithelial 
cancers. Imanaka Y et al. have found that miR-141 has an important regulatory function in the 
development of cisplatin resistance in cisplatin-resistant esophageal squamous cell carcinoma 
(ESCC) by directly targeting the 3'-untranslated region of YAP1[60]. MiR-141 is highly 
expressed in cisplatin-resistant esophageal cancer cell lines, and when expressed ectopically 
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in cisplatin-sensitive cell lines, cell viability after cisplatin treatment is increased significantly. 
Wu Y et al. have found that miR-200c is up-regulated in endometrial and esophageal cancers, 
and its overexpression correlates with resistance to cisplatin treatment. miR-200c may 
recognize the miRNA response element (MRE) in the 3'UTR of the AP-2 gene[61]. miR-200c 
expression correlates significantly with response to chemotherapy in esophageal cancers. 
Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated 
through activation of the Akt signaling pathway[62]. Taken together, miR-200c may induce 
cisplatin resistance by regulating AP-2 expression and the Akt signaling pathway. In EAC, 
miR-148a expression levels are inversely associated with cancer differentiation[63]. miR-148a 
improves response to chemotherapy in sensitive and resistant esophageal cancer cells. Up-
regulation of miR-148a may significantly increase sensitivity to chemotherapy in esophageal 
cancer cell lines, represented by a decrease in cell viability after 5-FU treatment. In addition 
miR-148a can sensitize chemotherapy-sensitive oesophageal cancer cell lines to cisplatin and 
attenuate resistance in chemotherapy-resistant variants. There is a trend toward a better 
response to 5-FU in 5-FU sensitive and resistant cells following miR-148a transfection. miR-
296 is involved in many physiological and pathological processes, such as tumorigenesis, 
fetal alcohol syndrome, insulin production as well as insulin secretion[64]. Down-regulation of 
miR-296 may inhibit growth of esophageal cancer cells in vitro and in vivo through regulation 
of cyclin D1 and p27. Down-regulation of miR-296 can confer sensitivity of drugs on 
esophageal cancer cells, and may promote adriamycin(ADR)-induced apoptosis, accompanied 
by increased accumulation and decreased release of ADR, through regulation of P-
glycoprotein, Bcl-2 and Bax[65]. miR-27a is widely expressed in cancer cells and may function 
as an oncogene through regulating cell survival and angiogenesis[51]. Down-regulation of 
miR-27a may confer sensitivity toward drugs representing targets for P-glycoprotein or not to 
esophageal cancer cells, and also promotes ADR-induced apoptosis, accompanied by 
increased accumulation and decreased releasing amount of ADR. Down-regulation of miR-
27a can significantly decrease the expression of P-glycoprotein, Bcl-2, and the transcription 
of the multidrug resistance gene 1 (MDR1), but upregulate the expression of Bax. In addition, 
downregulation of miR-483 and miR-214 may reverse drug resistance of esophageal cancer 
cells to ADR, 5-FU and cisplatin through regulation of intracellular drug accumulation and 
releasing index[66].  
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Table 1. Summary of miRNAs associated with chemoresistance of esophageal cancer.  
miRNA Rersistence Drugs Cancer 
miR-301a Down Radiation ESCC[67] 
miR-483/214 Up Adriamycin, 5-FU, Cisplatin ESCC[66] 
miR-21-3p Up 5-FU EAC[68] 
MiR-222-3p Up 5-FU EAC[69] 
miR-193b-3p/5p Up 5-FU EAC[69] 
miR-378 a-3p Down 5-FU EAC[69] 
miR-192-5p Down 5-FU EAC[69][46] 
miR-22 Down Radiation ESCC[70] 
Let-7 Down Cisplatin ESCC[52] 
miR-31 Down Radiation EAC[71] 
miR-31-5p Down Cisplatin EAC[47] 
miR-31-5p Up 5-FU ESCC[47] 
miR-125a-5p Down Cisplatin/5-FU EAC, ESCC[72] 
miR-141 Up Cisplatin ESCC[66] 
miR-200b/c/429 Up Cisplatin ESCC [61,62] 
Mir-148a Down Cisplatin ESCC[63] 
miR-27a Up Adriamycin ESCC[51] 
 
In our preliminary study, we successfully developed cisplatin or 5-FU resistant oesophageal 
cancer cells and identified stem-like side population (SP) and non-side population (NSP) cells. 
Several miRNAs (miR-21, miR-200c, miR-221, miR-34a, miR-155 and miR-92a) were 
upregulated in resistant cancer cells or SP cells compared with the sensitive cell or NSP 
cells[31]. These results suggested that miRNAs might play a role in the chemoresistance of 
oesophageal cancer. In this project, we further investigate the functional mechanism of 
miRNAs in chemotherapy resistance in oesophageal cancer cells. 
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Aim of study  
Chemotherapeutic resistance of esophageal cancer is a main obstacle in the treatment of 
esophageal cancer. But the mechanisms of chemoresistance of esophageal cancer are still not 
clear. In this study, we focus on the analysis of miR-221 with respect to chemoresistance of 
esophageal cancer. miRNAs play an important role in chemoresistance of various cancers. In 
our preliminary work, we found dysregulation of several miRNAs in 5-FU resistant 
esophageal cancer cell lines.  
Chemoresistance of cancer is a complicated and multistep process occurring during long term 
anticancer therapy. A variety of signal transduction pathways participate in that process 
including the Wnt pathway and EMT. In this study, we investigated whether Wnt pathway 
and EMT are involved in the 5-FU resistance of esophageal cancer. Previously published 
studies demonstrated that miR-221 can regulate cell proliferation of varieties of cancers by 
targeting the Wnt pathway or EMT [73–77]. Our preliminary data investigates that 5-FU 
resistance of esophageal cancer in our experimental model is regulated by miR-221 targeting 
Wnt pathways. We believe that miR-221 might be a good therapeutic target for esophageal 
cancer. 
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Materials and Methods 
1. Materials  
1.1  Cell lines 
Human esophageal cancer cell lines JROECL19 (OE19), JROECL33 (OE33), PT1590 and 
LN1590 were used in this study. The first two cell lines were obtained from Sigma company 
(ECACC number: 96071721 and 96070808). The other two cell lines were kindly donated by 
the University Medical Center of Hamburg-Eppendorf.  Origin and characteristics of these 
four cell lines are summarized below: 
 
 
Figure IV. OE19 cell: this cell line was established in 1993 from an adenocarcinoma of 
gastric cardia/esophageal gastric junction of a 72 year old male patient. The tumor was 
identified as pathological stage III (UICC) and showed moderate differentiation. Details can 
be found at  
 (http://www.sigmaaldrich.com/catalog/product/sigma/96071721?lang=en&region=CA).  
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Figure V. OE33: this cell line was established from the adenocarcinoma of the lower 
esophagus (Barrett′s metaplasia) of a 73 year old female patient. The tumor was identified as 
pathological stage IIA (UICC) and showed poor differentiation. Details can be found at 
 (http://www.sigmaaldrich.com/catalog/product/sigma/96070808?lang=en&region=CA) 
 
 
Figure VI. PT1590: this cell line was established from a primary tumor (PT) from a patient 
who was identified as stage IIB and had undergone radical esophagectomy for a poorly 
differentiated adenocarcinoma of the esophagus at the University Medical Center of 
Hamburg-Eppendorf. 
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Figure VII. LN1590: this cell line was established from a lymph node with micro-metastasis 
(LN) from a patient who was identified as stage IIB and had undergone radical 
esophagectomy for a poorly differentiated adenocarcinoma of the esophagus at the University 
Medical Center of Hamburg-Eppendorf. It was generated from one of Ber-EP4-positive nodes 
(later known as EpCAM).  
1.2  Animals 
The 6-8 week old, 20-22 g Bagg-albino/c (BALB/c) nu/nu male mice were bought from 
Charles River, Sulzfeld, Germany.  
1.3  Vectors 
1) TOP/FOP Flash luciferase reporter gene vectors: The TOP/FOP flash luciferase 
reporter gene vectors were a kind gift from Dr. Andreas Herbst, University of Munich.   
2) PCH110 β-galactosidase encoding plasmid: this plasmid was a kind gift from Dr. 
Andreas Herbst, University of Munich.  
3) The pGL3 Luciferase Reporter Vectors: The pGL3 Luciferase Reporter Vectors, used 
in this study, provide a basis for the quantitative analysis of factors that potentially 
regulate mammalian gene expression. These may be cis- or trans-acting factors. The 
backbone of the pGL2 Luciferase Reporter Vectors was re-designed for the pGL3 
Vectors for increased expression, with a modified coding region for firefly (Photinus 
pyralis) luciferase that has been optimized for monitoring transcriptional activity in 
transfected eukaryotic cells. The assay of this genetic reporter is rapid, sensitive and 
quantitative. 
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Figure VIII. pGL3 control vector: it contains SV40 promoter and enhancer sequences, 
resulting in strong expression of luc+ in many types of mammalian cells. The open reading 
frame (ORF) allows interchange of DNA inserts at upstream positions relative to the 
luciferase reporter gene. Thus, positional effects of a putative genetic element may be readily 
tested.  
1.4  Materials for qRT-PCR  
All stars negative control siRNA with /without Alexa fluor 488 
modification 
Qiagen, USA 
HiperFect transfection reagent Qiagen, USA 
Hsa_Mir-221 miscript primer assay Qiagen, USA 
Hsa_RNU6B miscript primer assay Qiagen, USA 
miRNeasy mini kit Qiagen Qiagen, USA 
miScript reverse transcription kit Qiagen, USA 
miScript SYBR Green PCR kit Qiagen, USA 
SuperScript III Platinum SYBR Green One-Step qRT-PCR kit Invitrogen,  USA 
QuantiFast SYBR Green PCR kit Qiagen, USA 
RT2 First start kit SuperArray Bioscience Qiagen, USA 
RT2 Profiler PCR array system SuperArray Bioscience Qiagen, USA 
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Table 2. Primers  
Gene symbol  Sequence 
TS Forward  5’-ACCAACCCTGACGACAGAAG -3’  
Reverse  5’-CATGTCTCCCGATCTCTGGT-3’  
DKK2 Forward 5’-CCAGTACCCGCTGCAATAAT -3’  
Reverse 5’-ATGACCGTGGTTTCGATCTC -3’  
CTNNB1 Forward 5’-GAGGGTACGAGCTGCTATGT-3’ 
Reverse 5’-AACGCTGGACATTAGTGGGA-3’ 
CDH1 Forward 5’- GAAGCTGGCTGACATGTACG-3’ 
Reverse 5’- CTCAAGGGAAGGGAGCTGAA-3’ 
VIM Forward 5’- AGGAACCAATGAGTCCCTGG-3’ 
Reverse 5’- GAAGGTGACGAGCCATTTCC-3’ 
Reverse 5’- TTTCTAGACTGGGCATCGCA-3’ 
DKK2 3’UTR 
repoter construct 
Forward 5’-CGGGTACCCAGGTTGCTATAAGCTTGGTGA-3’ (KpnI)  
Reverse 5’-GCAGATCTCCTAAATTACAAAGTCAATAGCTG-3’ (BglII)  
DKK2 Mut  3’UTR 
reporter construct 
Forward 5’- GCGGGTACCTTTCTTATGTCCACCCTT-3’(KpnI) 
Reverse 5’-GCAGATCTCGCTGTAAGCTTTCTGTAAG-3’(BglII) 
Mut, mutated   
Table 3. Sequence of miRNAs 
Name Sequence 
hsa-miR-21-5p  5 -́UAGCUUAUCAGACUGAUGUUGA-3  ́ 
hsa-miR-221-3p  5 -́AGCUACAUUGUCUGCUGGGUUUC-3  ́ 
hsa-miR-34a-5p  5 -́UGGCAGUGUCUUAGCUGGUUGU-3  ́ 
hsa-miR-200c-3p  5 -́UAAUACUGCCGGGUAAUGAUGGA-3  ́ 
hsa-miR-92a  5 -́UAUUGCACUUGUCCCGGCCUGU-3  ́ 
hsa- let-7b-5p  5 -́UGAGGUAGUAGGUUGUGUGGUU-3  ́ 
hsa- let-7g-5p  5 -́UGAGGUAGUAGUUUGUACAGUU-3  ́ 
 
1.5  Chemical reagents 
DMSO (Dimethylsulphoxide) Sigma-Aldrich, Steinheim, Germany 
DPBS buffer  Biochrom AG, Berlin, Germany 
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EGF (Recombinant human EGF) PeproTech EC, UK 
Fetal bovine serum Biochrom AG, Berlin, Germany 
FGF (Recombinant human basic FGF) PeproTech EC, UK 
Insulin solution (human) Sigma-Aldrich, Steinheim, Germany 
Normocin InvivoGen, San Diego, USA 
Penicillin/Streptomycin 100 ml  
(10.000 Units Penicillin/ml,  
10 mg Streptomycin/ml) 
PAN Biotech, Aidenbach, Germany 
RPMI 1640 + Glutamax-1 Gibco Invitrogen, Germany 
Trypsin 0.05%/EDTA 0.02 % in PBS 
without Ca2+ and Mg2+ 
PAN Biotech, Aidenbach, Germany 
Trypan blue (0.4%) Sigma-Aldrich, Steinheim, Germany 
Transferin Sigma-Aldrich, Steinheim, Germany 
1.6  Materials for Western blot, flow cytometry, immunofluorescence, and 
immunohistochemistry 
4% paraformaldehyde Pathology LMU, Germany 
Albumin from bovine serum (BSA)  Sigma-Aldrich, Steinheim, Germany 
Avidin/Biotin blocking kit  Vector Laboratories, CA, USA 
BCA protein assay reagent kit  Pierce Rockford, USA 
Biotinylated secondary antibody  Vector Laboratories, CA, USA 
DAPI in mounting medium  Vector Laboratories, CA, USA 
ECL Western blotting detection system Amersham Biosciences, Germany 
Ethanol 70%, 80%, 96%, 100%  CLN GmbH, Niederhummel, Germany 
FCR blocking reagent (human)  Miltenyi, Biotec GmbH, Germany 
Neo-Clear (Xylene substitute)  Merck, Darmstadt, Germany 
Hydrogen peroxide 30% (H2O2)  Merck, Darmstadt, Germany 
Kaiser’s glycerol gelatin  Merck, Darmstadt, Germany 
Liquid DAB+ substrate chromogen system Dako, CA, USA 
Mayer’s hemalum solution Merck, Darmstadt, Germany 
Normal rabbit serum  Vector Laboratories, CA, USA 
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Normal goat serum  Vector Laboratories, CA, USA 
Propidium iodide  BD phamingen, USA 
Restore Western blot stripping buffer  Pierce,Rockford, USA 
Sodium chloride Merck, Darmstadt, Germany 
Target retrieval solution 10×  Dako, CA, USA 
TRIZMA base Sigma-Aldrich, Steinheim, Germany 
TRIZMA hydrochloride  Sigma-Aldrich, Steinheim, Germany 
Triton X-100  Sigma-Aldrich, Steinheim, Germany 
Vectastain ABC kit  Vector Laboratories, CA, USA 
Verapamil hydrochloride (verapamil)  Sigma-Aldrich, Steinheim, Germany 
Flow cytometry tubes Belgium BD Bioscience Europe 
BD Falcon 5 ml polystyrene round-bottom tubes 
 (REF 352052) 
 
BD Falcon 5 ml polystyrene round-bottom tubes 
 with cell strainer cap (REF 352235) 
 
BD Falcon 5 ml polypropylene round-bottom tubes with cap (REF 352063  
Table 4. Antibodies   
Antibody 
Company Specifity Host Catalog Molecular 
weight 
Isotype 
DKK2 Abcam Human Rabbit ab38594 28kDa IgG 
E-cadherin Santa Cruz Human Mouse SC8426 120 kDa IgG1 
CD31 Abcam Mouse Rabbit ab28364   
Ki67 Abcam Human Rabbit ab16667   
β-actin Sigma Human Mouse A5316 42 kDa IgG2a 
β-catenin BD bioscience Human Mouse 610154 92 kDa IgG1 
TS Abcam Human Mouse ab3145 35(36 kDa) IgG1 
Vimentin Santa Cruz Human Rabbit SC7557-R 57 kDa IgG 
CyTM3 Jackson 
 ImmunoResearch 
Mouse Donkey 715-165-150  IgG 
CyTM2 Jackson  
ImmunoResearch 
Rabbit Goat 111-225- 
144 
 IgG 
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1.7  Technical equipments 
ABI Prism 7500 Applied Biosystems, Foster City, USA 
Automatic Tissue Processors Model 2065/2  MDS Group GmbH, Buseck, Germany 
Automatic pipettes Gilson, Middleton, WI, USA 
Axioskop 40, AxioCam MRc5 Digital fluorescence Carl Zeiss AG, Oberkochen, Germany 
Centrifuges  Eppendorf, Germany 
CO2 incubators  Heraeus, Rodenbach, Germany 
Digital precision scale  K ERN & Sohn GmbH, Germany 
FACS Calibur  BD Biosciences, USA 
Freezer -20°C  Siemens AG, Germany 
Freezer -80°C Heraeus, Hanau, Germany 
Fridge 4°C Siemens AG, Germany 
Hand tally counter Carl Roth GmbH, Karlsruhe, Germany 
Herasafe EN12469 2000 Class II safety cabinet  Thermo Fisher Scientific Inc, Germany 
Leica RM2255, Fully Motorized Rotary Microtome Leica Microsystems, Germany 
LSR II flow cytometry BD Biosciences, USA 
Liquid nitrogen tank  MVE, New Prague, MN, USA 
Phase contrast microscope Carl Zeiss GmbH, Germany 
Microwave oven Siemens, Germany 
MoFlo high speed sorter 
DAKO Cytomation, Glostrup, 
Denmark 
Thermo Scientific Heraeus incubator Thermo Fisher Scientific Inc, Germany 
TECAN GENios Plus ELISA reader TECAN, Salzburg, Austria 
RNA/DNA calculator  GeneQuant Pro, GE, USA 
Vortex  IKA Works, Wilmington, NC, USA 
Water bath GFL, Burgwedel, Germany 
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1.8  Cell culture materials 
5 ml coster stripette Corning Inc, New York, USA 
10 ml coster stripette Corning Inc, New York, USA 
25 ml coster stripette Corning Inc, New York, USA 
25 cm2 nunc sterile tissue culture flasks  Thermo Fisher Scientific Inc, Denmark 
75 cm2 nunc sterile tissue culture flasks  Thermo Fisher Scientific Inc, Denmark 
150 cm2 nunc sterile tissue culture flasks Thermo Fisher Scientific Inc, Denmark 
15 ml centrifuge tubes TPP, Switzerland 
50 ml polypropylene conical tubes BD Bioscience Europe, Belgium 
6, 12, 24 and 96-well nunc delta surface culture 
 Plates 
Thermo Fisher Scientific Inc, Denmark 
12 and 24-well companion plate notched for use 
 with cell culture insert 
BD Dicknson Labware, USA 
Cell culture insert 8.0 μm BD Bioscience, NJ, USA 
Lab-Tek™ chamber slides Thermo Fisher Scientific Inc, USA 
Nunc cryotube (2.0 ml) Thermo Fisher Scientific Inc, Germany 
Eppendorf safe- lock tubes (0.6 ml, 1.5 ml, 2.0 ml) Eppendorf AG, Hamburg, Germany 
Hemacytometer and cover slip (Cell counting 
 chambers) 
Bürker-Türk, Germany 
 
1.9  Materials for cell proliferation and cytotoxicity assay 
5-FU (Fluorouracil-GRY) GRY-Pharma GmbH, Germany 
Cell counting kit-8 (CCK-8) Dojindo Laboratories, Japan 
AnnexinV-FITC Apoptosis Kit R&D systems, Minneapolis, USA 
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1.10 Materials for transfection 
Hiperfect transfection reagent Qiagen, USA 
X-tremeGENE HP DNA Transfection Reagent Roche,USA 
Lipofectamine-2000 Invitrogen, USA 
SiRNA-CTNNB1 Gel Health Care, Germany 
SiRNA Control Gel Health Care, Germany 
Hsa-miR-221 mimic Qiagen, USA 
Hsa-miR-221 inhibitor Qiagen, USA 
Control siRNA Qiagen, USA 
miScript Inhibitor Negative Control Qiagen, USA 
 
Table 5. Target sequence of CTNNB1 siRNA pool 
Name Target Sequence 
siGENOME SMARTpool siRNA-CTNNB1-1  GCUGAAACAUGCAGUUGUA  
siGENOME SMARTpool siRNA-CTNNB1-2  GAUAAAGGCUACUGUUGGA  
siGENOME SMARTpool siRNA-CTNNB1-3  CCACUAAUGUCCAGCGUUU  
siGENOME SMARTpool siRNA-CTNNB1-4  ACAAGUAGCUGAUAUUGAU  
 
1.11 Surgical materials 
BODE Cutasept F  Bode Chemie, Hamburg, Germany 
Disposable scalpels Feather Safety Razor Co., Japan 
Forceps  Dosch GmbH, Heidelberg, Germany 
Hypodermic needle (30 G)  B-Braun, Melsungen, Germany 
Needle holder  Dosch GmbH, Heidelberg, Germany 
Isotonic saline  B-Braun, Melsungen, Germany 
Q-tips (cotton applicator)  NOBA, Wetter, Germany 
Rotilabo-embedding cassettes Carl Roth GmbH, Karlsruhe, Germany 
Scissors, sharp / blunt Dosch GmbH, Heidelberg, Germany 
Syringe (1 ml, 5 ml)  BD PlastipakTM, Madrid, Spain 
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1.12 Medicine 
Growth Factor Reduced (GFR)  BD 
MatrigelTM Matrix, 10 ml BD Biosciences, USA 
Ketamin hydrochlorid (Ketavet) 100 mg/ml  Pfizer Pharmacia GmbH, Germany 
Xylazin hydrochlorid, Xylazin (Rompun) 2% 25 ml Bayer Healthcare, Leverkusen, 
 Germany 
1.13 Software 
Adobe Acrobat 7.0 Professional Adobe  Systems Inc., USA 
Axio Vision 4.4 Carl Zeiss GmbH, Germany 
EndNote X5 (Windows Version X5) Thomson Reuter, CA, USA 
Graphpad Prism 6.0 GraphPad Software, Inc., USA 
Image-Pro Plus 5.0 Media Cybernetics, Inc., USA 
Microsoft Office 2007 (Word, Excel,  
PowerPoint) Microsoft 
Corporation, USA 
SoftMax Pro Molecular Devices Corp., USA 
Summit 4.3 software Beckmann coulter GmbH, Germany 
Windows XP Professional Microsoft Corporation, USA 
Venn online 
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2. Methods 
2.1  Establishment of chemoresistant esophageal cancer cell lines and cell culture 
1) Cell culture : Human esophageal cancer cell lines OE19, OE33, PT1590 and LN1590 
were used in this study. The first two cell lines were cultured in RPMI1640 
supplemented with 2 mM glutamine, 10% fetal bovine serum, 1% penicillin and 1% 
streptomycin. The other two cell lines were cultured in RPMI1640 medium with 2  
mM glutamine, 10% fetal bovine serum, 1% penicillin and 1% streptomycin, 10 ng/ml 
EGF, 10 ng/ml FGF, 10ng/ml insulin and 4 μg/ml transferrin. All cell lines were kept 
at 37°C in a humidified incubator containing 5% CO2. 
2) Establishment of chemotherapy resistant cell lines: IC50 of 5-FU was determined 
by cell cytotoxicity assay. The 5-FU-resistant esophageal cancer cell lines (OE19-
5FUres, OE33-5FUres, PT-5FUres and LN-5FUres) were developed through a stepwise 
incremental treatment with 5-FU as follows: the initial concentration of 5-FU used 
was set at 5 μg/ml based on IC50 values ranging between 3 and 6.5 μg/ml for the 
parental cell lines. After 24 hours, the cells were passaged with 5-FU free medium. 
Upon reaching confluent growth, the cells were treated with increased levels of 5-FU 
(1.5 to 2-fold). Over five subsequent increases in 5-FU exposure using the same 
procedure, 5-FU-resistant cell lines (OE19-5FUres, OE33-5FUres, LN-5FUres and PT-
5FUres) were eventually established. The 5-FU resistant cells cultured in complete 
medium were continuously exposed to 5-FU with stepwise increased concentrations 
according to the IC50 value (from 10% IC50 up to 5 fold IC50) respectively. Medium 
was changed twice a week.  
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Figure IX. Establishment of 5-FU resistant esophageal cancer cell lines. The above human 
esophageal cancer cell lines were developed through a stepwise increment of 5-FU 
concentration as follows: the initial concentration of 5-FU was around 5 μg/ml and, after 3 
days, the cells were passed through a 5-FU free medium. Upon reaching confluence, the cells 
were treated with a higher concentration of 5-FU (1.5 to 2- fold). Over five subsequent 
increases in 5-FU exposure using the same procedure, 5-FU-resistant cell lines (OE19-5FUres, 
OE33-5FUres, LN-5FUres and PT-5FUres) were eventually established. Medium was changed 
twice a week. 
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2.2  RNA isolation and quantification of miRNA or target gene expression 
1) RNA isolation: Total RNA was isolated from 5-FU sensitive and resistant esophageal 
cancer cells according to the manufacturer of miRNeasy mini kit as shown in Figure X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure XI. Isolation of total RNA. Total RNA was isolated from 5-FU sensitive and resistant 
esophageal cancer cells as recommended by the manufacturer of the miRNeasy kit. 100 ng of 
total RNA was used to prepare cDNA fragments for further quantification.  
2) RT-qPCR for miRNAs : The cDNA was synthesized with miScript II RT Kit according 
to the manufacturer’s instructions. Then the expression of miRNAs was quantified by 
using the miScript SYBR® Green PCR Kit according to the manufacturer's instructions.  
MiRNAs expression was related to the RNU6B internal control. Data was calculated 
using the 2−ΔΔCT  method.  
Add Trizol and homogenize 
 
  
cells 
Add Chloroform and separate phases 
Transfer the upper aqueous phase to a new collection tube 
Add ethanol and bind to spin column 
Wash 
 
Elute total RNA 
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3)  RT-qPCR for target genes 
The expression of miRNA target genes were detected by Quanti Fast SYBR Green PCR 
Kit and normalized by GAPDH mRNA. Data was calculated using the 2-ΔΔCT  method.  
2.3  Typan blue staining and CCK-8 assay 
The cell viability was assessed by trypan blue staining. 10-100 μl of single cell suspension 
were gently mixed with an equal volume of 0.4% trypan blue. The calculation is as below: 
        Cell viability = [unstained cells/(unstained + trypan blue stained cells)]× 100% 
CCK-8 assay was performed for cell proliferation and cytotoxicity according to the 
manufacturer’s instructions. For cell proliferation measurement, 1x104 cells per well with or 
without transfection of miR-221 mimics or inhibitors, were seeded in a 96-well plate, grown 
over night, and cell viability was measured after 0 h, 24 h, 48 h, and 72 h according to the 
manufacture’s instruction. For cell cytotoxicity assay, cells were seeded in a 96-well plate as 
before, further treated with 5-FU for 48 h, and analyzed as before using VersaMax tunable 
microplate reader and Softmaxpro 6.2 for data analysis. 
2.4  Prediction of miR-221 target genes 
Target genes of miR-221 were predicted using 4 microRNA-target predict tools:  
TargetScan:  http://www.targetscan.org/,  
PITA: http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html,  
miRTarBase:  http://mirtarbase.mbc.nctu.edu.tw/  
 miRanda:  http://www.microrna.org/microrna/home.do 
The intersection of miR-221 target genes was analyzed by Venn online. The secondary 
structure of miR-221 and its target gene was predicted by RNAhybrid 
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/).  
2.5  Luciferase reporter assay 
Construction of luciferase reporter vectors : The 3’-UTR segments of DKK2, containing 
the putative binding sites for miR-221, were synthesized by PCR. The primers are shown in 
Table 1. After appropriate digestion and purification, the products were separately cloned into 
the KpnI and BglII sites on the pGL3-control vector (Promega, Madison, WI) downstream of 
the luciferase gene to generate wild type or mutant pGL3-DKK2 constructs.  
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Figure XII. Design of luciferase reporter vectors. The 3’-UTR segments (244 bp) of DKK2, 
containing the putative binding sites for miR-221, were cloned into the restriction sites KpnI 
and BglII sites upstream of the luciferase reporter gene.  
Luciferase reporter assay: 1 x 105 OE33 cells were seeded per well (12-well plate). Cells 
were transfected with miR-221 mimics and wt-pGL3-DKK2, mut-pGL3-DKK2 or pGL3-
control using Lipofectamine-2000 (Invitrogen). The samples were also co-transfected with 50 
ng of pRL-TK plasmid expressing Renilla luciferase as normalisation controls. Then, cells 
were harvested 24 h after transfection, and firefly and Renilla luciferase activity levels were 
measured by using the Dual-Luciferase Reporter Assay (Promega, USA). Each transfection 
was performed in triplicate.  
2.6  TOP/FOP flash luciferase report assay 
To assess TCF/β-catenin-mediated transcriptional activity, TOP-flash luciferase reporter gene 
assays were performed using the Luciferase Reporter Assay System (Promega, Madison, WI, 
USA) according to the manufacturer’s instructions. 1x105 OE33 and OE33-5FUres cells were 
seeded per well (12 well plate). Cells were transfected with 5 nM hsa-miR-221 mimics (miR-
221), 50 nM hsa-miR-221 inhibitors (anti221) or 5 nM siR-CTNNB1 (siR-β) using 3 μl the 
Hiperfect transfect reagent. 24 h later, 1 μg the 8 x TOP-flash reporter gene construct or 1 μg 
8 x FOP-flash reporter gene construct (a generous gift from PD Dr. Andreas Herbst, 
University of Munich, Germany) as well as 1μg the plasmid pCH110 encoding β-
galactosidase (a generous gift from PD Dr. Andreas Herbst, University of Munich, Germany) 
were transfected into these cells using 3 μl X-treme GENE HP DNA transfection reagent. 72 
h after siRNA transfection, cells were harvested and lysed with reporter lysis buffer (Promega, 
USA), and luciferase activities were measured using a luciferase assay reagent (Promega, 
USA) and a luminometer (Orion II, Berthold Detection Systems, Wildbad, Germany). β-
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galactosidase activity was determined by standard methods using o-nitrophenyl β-D-
galactopyranoside (ONPG, Sigma-Aldrich, Taufkirchen, Germany) as a normalisation control.  
2.7  Western blot analysis 
Cell lysate preparation: After washing twice with 1x PBS, cells in a 10 cm dish were 
scraped off the plate and transferred to a 1.5 ml tube. Lysis buffer was added directly into the 
tube and the tube was incubated at room temperature for 15 min. The cell lysate was finally 
centrifuged at 16,000 g at 4 °C for 15 min. The supernatant was aliquoted and stored at -80 °C.  
Protein concentration measurement: Protein concentrations were measured with the BCA 
protein assay. A serially diluted bovine serum albumin solution (2 mg/ml) was used as a 
standard. 5 μ l of protein lysate were diluted with 95 μl ddH2O and 100 μl BCA reagent were 
added in duplicate into a 96-well plate at a final volume 200 μl per well. The plate was 
incubated at 37℃  for 30 min before the absorbance was measured at 562 nm with a 
microplate reader. 
Gel electrophoresis: The cell lysates were mixed with 5x loading buffer (4 volumes of 
sample + 1 volume of loading buffer), heated at 95 °C for 5-10 min and centrifuged at 
16,000g at 4 °C for 5 min. The samples were then applied to 8-16% polyacrylamide gels. 6μl 
marker was loaded as molecular weight standard. The running condition was 65  V for 20 min 
and 100 V for 1 h-1.5 h at RT.  
Transfer: After separation, proteins were transferred to a PVDF membrane in a semi-dry 
transfer chamber. Before transfer, the membrane was soaked in methanol for 1 min. The 
transfer took place in a semidry transfer unit at a constant torrent of 200 mA for 1 h at RT.  
Blotting: After transfer, the PVDF membrane was washed in 1x TBST for 5 min on a shaker 
and then blocked in blocking buffer (5% milk in 1 x TBST) for 2 h at RT.  Subsequently, the 
membrane was incubated with the primary antibodies (diluted in 1 x TBST with 5% milk) 
overnight at 4 °C on a rotating platform. The membrane was washed three times in 1 x TBST 
for 5 min and then incubated with the corresponding horseradish peroxidase (HRP)-
conjugated secondary antibodies for 2 h at room temperature. Finally, the membrane was 
washed again three times for 5 min with 1  x TBST buffer and once with 1 x PBST. The 
detection was performed using the enhanced chemiluminescense system. β-actin detection 
was used to ensure equal protein loading. 
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2.8  Immunofluorescence staining 
48 h after transfection with miR-221 mimics or inhibitors, 5-FU sensitive or resistant 
esophageal cancer cells were fixed with 4% paraformaldehyde for 15 min at room 
temperature, washed with 1 x PBS for 5 min, permeabilized with 0.1% Triton X-100 in 
blocking serum for 30 min at room temperature, and finally incubated with anti-β-catenin 
antibody (dilution 1:200) at 4°C overnight. After the cells were stained with a matched Cy3-
conjugated secondary antibody (dilution 1:200) for 1 h at room temperature, the chamber 
slides were counterstained with DAPI in mounting medium and visualized by d igital 
fluorescence microscopy using the AxioVision Rel. 4.6 software. For further image 
processing and analysis the software Image-pro was used. 
2.9  Immunohistochemistry and immunfluorescence analysis for Ki67 and CD31 
Tissue sections (4 μm) were deparaffinized in xylene and rehydrated in a graded series of 
ethanol. Endogenous peroxidase was blocked by incubation with 3% hydrogen peroxide  
followed by antigen retrieval using antigen retrieval solution. Endogenous avidin and biotin 
were blocked with the Avidin/Biotin blocking kit. The slides were treated for 20 min with 
blocking solution followed by overnight application of anti-Ki67 antibody as primary 
antibody. Then biotinylated secondary antibody as well as the ABC reagent for signal 
amplification was applied. Slides were washed in TBS buffer, stained with DAB and counter-
stained with hematoxylin and then mounted in Kaiser’s glycerol gelatin.  
Frozen tissue sections were fixed with 1% paraformaldehyde for 20 min and then washed 2 
times with 1 x PBS. 10% goat serum was added for blocking the non-specific biding sites. 
Frozen tissue sections were stained with 1:100 diluted CD31 antibody at 4 ℃ overnight. After 
washed 2 times with 1x PBS, all sections were incubated with a DAPI nuclear counterstaining.   
Finally slides were analyzed at 200x magnification with a fluorescence microscope. Areas 
presenting the highest density of CD31 positive cells were chosen and captured as 
photographs. These photographs were analyzed by Image-J program. The Ki67 or CD31 
index were evaluated in a blinded manner and calculated as Ki67 or CD31 positive cells in 
one field. Necrotic tumor cells were excluded from the cell count. MVD (Micro vascular  
density) was evaluated by CD31 positive structures that were identified for vessel counts. 
37 
2.10 In vivo subcutaneous esophageal cancer animal model 
BALB/c nu-nu male mice were obtained from Charles River Deutschland (Sulzfeld, Germany) 
at 6-8 weeks of age and housed in the animal facility of the University Medical Center 
Magdeburg. These mice were divided into six groups (5 mice per group): 
Group 1: OE33 + PBS (OE33 Ctrl) (n=5) 
Group 2: OE33 + negative control siRNA (OE33 + siRCtrl) (n=5) 
Group 3: OE33 + miR-221 mimics (OE33 + miR-221) (n=5) 
Group 4: OE33-5FUres + PBS (OE33-5FUres Ctrl) (n=5) 
Group 5: OE33-5FUres + negative control siRNA (OE33-5FUres + siRCtrl) (n=5) 
Group 6: OE33-5FUres + anti221 inhibitors (OE33-5FUres + anti221) (n=5) 
1) All cells were harvested after trypsinization and washed 3 times with medium. A total of 
1 × 106 cells in a 200 μl suspension were subcutaneously injected into the flanks of mice 
with a 1ml syringe (BD Plastipak, Becton Dickinson S.A., Spain) with a 27-gauge 
hypodermic needle (Sterican, Braun, Germany) within 40 min of harvest.  
 
 
Figure XIII. Subcutaneous transplantation model of esophageal cancer.  First, OE33 and 
OE33-5FUres cells were seeded on 10 mm dishes and transfected with hsa-miR-221 mimics, 
hsa-miR-221 inhibitors and negative control siRNA, respectively.  The next day cells were 
collected and resuspended in PBS; 1 × 106 cells in a 200 μl suspension were subcutaneously 
injected into the flanks of mice with a 1 ml syringe with a 27-gauge hypodermic needle 
(Sterican, Braun, Germany) within 40 min of harvest.  
2) Mice were weighed and tumor sizes were measured for tumor development every three 
days. When the biggest tumor size reached around 10 mm in diameter, all tumors were 
collected and the data was analyzed. 
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2.11 Identification of validated β-catenin target genes related with EMT pathway 
Considering 5-FU resistance, Wnt/β-catenin pathway and EMT pathway in this study, we 
collected and summarized common cancer relevant genes among Wnt/β-catenin pathway and 
its targets, as well as EMT.  We were particularly interested in β-catenin target genes that are 
associated with EMT. For this reason, the PubMed database was searched using the phrase 
“(beta-catenin AND target) AND emt”. 135 articles were identified (as of 12 1st, 2014) and 
publications were screened for the identification and characterization of β-catenin target genes 
related to EMT. We were able to identify 30 published β-catenin target genes related to the 
EMT pathway that matched our criteria (Table 5) and 3 chemoresistance related markers: 
ABCG2, ABCB1 and ABCC2. 
Table 6. Candidate genes of EMT-related Wnt/β-catenin target genes 
AXIN2 BIRC5 BMP4 CCND1 CD44 CDH1 DKK1 
EGFR EPCAM FN1 FOS FZD7 GSK3B MMP2 
MMP7 MMP9 MSX2 MYC NANOG SNAI2 TCF4 
VIM WNT3A WNT5A ZEB1 EPHA2 SOX2 SNAI1 
TGFB3 JUN ABCG2 ABCB1 ABCC2   
 
2.12 RT2 Profiler PCR Array System 
The Custom Human RT2 Profile TM PCR array (RT Profiler TM PCR Array: CAPH12950) 
was performed for examining genes of interest including targets of Wnt pathway, which are 
associated with EMT and chemoresistance. Total RNA of 5x105 OE33 and OE33-5FUres cells 
with or without miR-221 mimics, inhibitors and siR-CTNNB1 transfection was isolated using 
the miRNeasy kit (Method 2.2). cDNA was synthesized from 500 ng of RNA using the RT2 
First Stand kit. PCR was performed with the RT2 Profile PCR array system according to the 
manufacturer's instructions using ABI 7500. The expression levels of different mRNAs were 
normalized using housekeeping genes expression of ACTB, B2M, GAPDH, HPRT1 and 
RPLP0. The fold change of each gene from treatment group to control group was calculated 
as 2(-ΔΔCT ). 
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2.13 Statistical analysis 
All data are expressed as mean ± SD. The correlation of β-catenin or DKK2 and each clinical 
pathologic variable was comparatively analyzed by the Fisher exact test and Chi-square test. 
A p value of less than 0.05 indicated the presence of statistically significant difference 
between groups. All statistical analyses were carried out with Graphpad Prism 6. For RT2 
profiler data analysis, we compared genes differently expressed in esophageal cancer cell 
lines OE33, OE33-5Fures cells after transfection with miR-221 mimic, inhibitors and siRNA-
CTNNB1 by a web-based service of Qiagen data analysis center.  Genes were called 
“differentially expressed” if the corrected P value was less than 0.05. 
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Results 
1. Establishment of esophageal cancer cell lines resistant to 5-FU 
At first we successfully established 5-FU resistant EC cell models from four different EC 
cells lines (OE19, OE33, PT1590 and LN1590). We compared the sensitivity of these 4 pairs 
of esophageal cancer cell lines to 5-FU by CCK-8 assays. The IC50 of 5-FU resistant EC cells 
was approximately 10 to 60 fold higher than that of parental cells as shown in Figure 1-1. The 
IC50 of the four 5-FU resistant esophageal cancer cells OE19-5FUres, OE33-5FUres, PT-
5FUres and LN-5FUres were 78.65±6.56 μg/ml, 102.80±8.94 μg/ml, 81.91±6.22 μg/ml and 
186.20±6.98 μg/ml, respectively. The IC50 of the 4 corresponding parental esophageal cancer 
cells were 4.29±0.84 μg/ml, 4.30±0.85 μg/ml, 6.53±0.70 μg/ml and 3.30±0.50 μg/ml, 
respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. IC50 of 5-FU sensitive and resistant esophageal cancer cells. The original IC50 
values for OE19, OE33, PT1590 and LN1590 were 4.3, 4.29, 6.53 and 3.3  μg/ml. The IC50 
values for OE19-5FUres, OE33-5FUres, LN-5FUres and PT-5FUres lines were 78.6, 102.8, 81.9, 
and 186.2 μg/ml respectively.  
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2. MiR-221 is upregulated in 5-FU resistant esophageal cancer cells  
In preliminary work on the function of miRNAs in 5-FU resistance of esophageal cancer cells 
we measured the level of several chemoresistance-related miRNAs (let-7b, let-7g, miR-21, 
miR-34a, miR-92, miR-200c and miR-221) in 5-FU sensitive and resistant esophageal cancer 
cell lines PT/PT-5FUres and LN/LN-5FUres. We found that miR-221 level in PT-5FUres and 
LN-5FUres was higher than that in parental cancer cell lines. The fold change was 6.69±0.43 
and 1.51±0.04, respectively (*p<0.05, **p<0.01 and ***p< 0.001) (Figure 2-1). Then we 
identified miR-221 expression in the other two pairs of esophageal cancer cell lines OE19-
5FUres and OE33-5FUres as well as their parental cells. Compared to OE19 and OE33 cells, 
miR-221 expression was higher in both OE19-5FUres and OE33-5FUres (**p<0.01, 
***p<0.001) (Figure 2-2).   
 
 
 
Figure 2-1. MiRNAs expression in 5-FU sensitive and resistant PT1590 and LN1590 cells.  
Compared to PT1590 and LN1590 cells, miR-221 expression in PT-5FUres and LN-5FUres was 
increased 6.69±0.43 and 1.51±0.04 fold respectively. *p<0.05, **p<0.01 and ***p< 0.001, t-
test. 
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Figure 2-2. MiR-221 expression in four pairs of 5-FU sensitive and resistant esophageal 
cancer cell lines. miR-221 was upregulated in all four 5-FU resistant esophageal cancer cell 
lines compared to their corresponding parental cancer cells. **p<0.01 and ***p<0.001, t-test. 
For further study, we separately increased and decreased miR-221 expression by transfecting 
miR-221 mimics into OE33 cells and the miR-221 inhibitors into OE33-5FUres; we conducted 
microRNA qPCR for determination of miR-221 expression to evaluate the transfection 
efficiency and the efficacy of miR-221 mimics and inhibitors. It was observed a dramatic 
increase of miR-221 expression in OE33 cells following transfection of miR-221 mimics and 
a decrease of miR-221 expression in OE33-5FUres following transfection of miR-221 
inhibitors. (**p<0.01, ***p<0.001) (Figure 2-3). 
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Figure 2-3. The efficacy of miR-221 mimics and inhibitors in EC cells. Compared to the 
corresponding control groups, the level of miR-221 in OE33 and OE33-5FUres cells was 
increased and decreased by miR-221 mimics and miR-221 inhibitors, respectively. While 
there was no significant difference of miR-221 expression in OE33 and OE33-5FUres cells 
with or without miRNA negative control and inhibitors negative control treatment. **p<0.01 
and ***p<0.001, t-test.  
 
3. Dysregulation of miR-221 regulates cell proliferation and 5-FU 
sensitivity in 5-FU sensitive and resistant EAC cells 
After transfection with miR-221 mimics or inhibitors in 5-FU sensitive or resistant esophageal 
cancer cells, we measured cell growth of esophageal cancer cells at 0 h, 24 h, 48 h and 72 h. 
We found miR-221 mimics can promote cell growth of 5-FU sensitive esophageal cancer 
cells, which was most significant at 48 h; and miR-221 inhibitors can suppress cell growth of 
5-FU resistant esophageal cancer cells at 48 h. (Figure 3-1) 
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Figure 3-1. Cell proliferation of 5-FU sensitive and resistant OE33 cells with or without miR-
221 mimics and inhibitors transfection. At 48 h after transfection, miR-221 mimics and 
inhibitors significantly promoted and inhibited cell growth of OE33 and OE33-5FUres cells, 
respectively. *p<0.05, **p<0.01, t-test. 
For assessing the cytotoxicity of esophageal cancer cells to 5-FU with or without miR-221 
mimics or inhibitors transfection, CCK-8 assay was performed to measure cell inhibition ratio. 
37.23±6.32 % OE33 cells and 6.28±0.67 % OE33-5FU cells were inhibited at 48 h after 2.5 
μg/ml 5-FU treatment. MiR-221 mimics did not significantly increase the resistance of OE33 
cells to 5-FU [33.43±1.47 % dead cells]; however, miR-221 inhibitors did significantly lift the 
5-FU sensitivity of OE33-5FUres [29.85±4.86% dead cells] (**p<0.01, Figure 3-2).  When we 
treated these cells with 20 μg/ml 5-FU, we got the same results. There were more dead OE33-
5FUres cells with low level of miR-221 [36.94±6.17% dead cells] (**p<0.01) (Figure 3-3). 
Moreover, we confirmed the effect of miR-221 inhibitors to suppress resistance by measuring 
the expression of the 5-FU target and resistance relevant marker thymidylate synthase (TS). 
The Western blot result showed that miR-221 mimics slightly increased TS protein expression 
in OE33 cells, while miR-221 inhibitors decreased TS protein expression in OE33-5FUres 
(Figure 3-4).  
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Figure 3-2. Sensitivity of OE33 and OE33-5FUres cells with or without miR-221 mimics and 
inhibitors treatment to 2.5 μg/ml 5-FU.  miR-221 mimics did not significantly decrease the 
sensitivity of  OE33 cells to 5-FU, but miR-221 inhibitors significantly increased the 
sensitivity of OE33-5FUres to 5FU. **p<0.01 and ***p<0.001, t-test. 
 
 
 
Figure 3-3. Sensitivity of OE33 and OE33-5FUres cells with or without miR-221 mimics and 
inhibitors after 20 μg/ml 5-FU treatment.  miR-221 mimics did not decrease the sensitivity of  
OE33 cells to 5-FU, but miR-221 inhibitors significantly increased the sensitivity of OE33-
5FUres to 5-FU. **p<0.01 and ***p<0.001, t-test. 
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Figure 3-4. The protein level of TS in OE33 and OE33-5FUres.  miR-221 mimics  increased 
TS protein expression slightly, while miR-221 inhibitors decreased TS protein level 
dramatically.  
4. Dysregulation of miR-221 regulates esophageal cancer growth in vivo 
OE33 tumor xenografts were established by subcutaneous injection of 1x106 OE33 and 
OE33-5FUres cells with or without miR-221 mimics/inhibitors transfection in the flanks of 
mice. At 66 days after injection, all mice were sacrificed. The tumor sizes are shown in Figure 
4-1. The tumors of the OE33-5FUres control group and the OE33+miR-221 group were 
significantly bigger than that of the OE33 control group. While the tumor of the OE33-5FUres 
+anti221 group was smaller than that of the OE33-5FUres control group. The tumor growth 
curve analysis revealed that overexpression of miR-221 significantly promoted tumor growth 
of 5-FU sensitive esophageal cancer, while the loss of miR-221 by its inhibitors dramatically 
suppressed tumor growth of 5-FU resistant esophageal cancer (Figure 4-2). To assess tumor 
cell proliferation and angiogenesis, K i67 and CD31 expression was detected by IHC staining 
and IF staining. The results were shown as Figure 4-3. In the OE33+miR-221 group, a clear 
increase of Ki67 and CD31 expression was observed compared to the OE33 control group. 
While there was a dramatic decrease of Ki67 and CD31 expression in the OE33-5FUres 
+anti221-group compared to OE33-5FUres control group. These results indicated that miR-221 
could influence tumor cell proliferation and angiogenesis in both 5-FU sensitive and resistant 
esophageal cancer.   
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Figure 4-1. Comparison of tumor sizes among 6 groups (5 mice/group). The tumors of the 
OE33-5FUres-control group and the OE33+miR-221-group were dramatically bigger than 
those of the OE33-control group, while tumors of the OE33-5FUres+anti221-group were 
smaller than those of the OE33-5FUres control group.  
 
 
 
Figure 4-2. In vivo tumorigenesis of esophageal cancer. Enhanced expression of miR-221 
promoted OE33 tumor growth in a xenograft nude mouse model and down-regulation of miR-
221 expression inhibited OE33-5FUres tumor growth. *p<0.05, **p<0.01, t-test.  
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Figure 4-3. Analysis of cell proliferation and angiogenesis in tumor. The proliferation marker 
Ki67 was substantially weaker expressed in the OE33-5FUres +anti221 group, as compared to 
the control group. The angiogenesis marker CD31 expression in OE33+miR-221 group was 
dramatically increased as compared with that in control group, while a reduction in CD31 
expression was seen in OE33-5FUres +anti221 group. 
 
5. MiR-221 acts pro-tumorigenicly by directly targeting DKK2 in EC 
To further investigate the molecular mechanism of miR-221 regarding its pro-tumorigenic 
ability, we determined its target genes in esophageal cancer by interrogating the interaction 
between miR-221 and its target mRNA transcripts. Candidate target genes were determined 
via four microRNA target prediction tools including TargetScan, PITA, miRTarBase and 
miRanda (Figure 5-1). 120 common candidate target genes were predicted by these 4 
prediction tools.  In these candidate target genes, we chose the gene DKK2 for further studies. 
DKK2 is an antagonist of the WNT pathway, which is associated to the development of 
esophageal cancer. The sequence of 3’UTR of DKK2 is conserved in wide variety of 
mammalian species such as human, chimpanzee, rat, mouse, rabbit, etc. The interactive 
capacity of miR-221 and 3’-UTR of DKK2 was analyzed using the miRNA target prediction 
tool RNAhybrid (Figure 5-2).  
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Figure 5-1. Prediction of miR-221 target genes by microRNA target prediction tools. 120 
candidate target genes with miR-221 seed sites were predicted via four different miRNA 
target prediction tools (TargetScan, PITA, miRTarBase and miRanda).  DKK2 was chosen for 
further study.  
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 Figure 5-2. Interaction of miR-221 and 3’UTR of DKK2. miR-221 could bind the bases from 
2058 to 2064 in the 3’-UTR of DKK2 predicted by TargetScan. The sequence of the DKK2 
3’UTR is conserved in different species: human, chimpanzee, rat, mouse, rabbit, etc. The 
interactive capacity of miR-221 and 3’UTR of DKK2 was analyzed using the miRNA target 
prediction tool RNAhybrid.  
To confirm the interaction of miR-221 and DKK2 analyzed by the miRNA targets prediction 
engine, we performed a series of assays to determine the direct target relationship between 
miR-221 and DKK2 in esophageal cancer cell lines. Overexpression of miR-221 by 
introducing miR-221 mimics in OE33 cells resulted in a significant reduction of DKK2 
mRNA transcription as well as protein expression (Figure5-3).  Reversely, down-regulation of 
miR-221 by its inhibitors enhanced DKK2 expression at both the mRNA and protein level in 
OE33-5FUres cells (Figure 5-3). 
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Figure 5-3. DKK2 expression in OE33 and OE33-5FUres cells. qPCR analysis showed that 
DKK2  mRNA levels were reduced in 5-FU resistant esophageal cancer cells, as compared to 
the 5-FU sensitive esophageal cancer lines. MiR-221 knockdown was shown to result in a 
significant increase in DKK2  mRNA and protein expression. *p<0.05, **p<0.01, t-test.  
Even though miRNAs are known to affect the translation of gene transcripts, we performed 
luciferase reporter assays to identify whether miR-221 directly targets the 3’-UTR of DKK2. 
Esophageal cancer cells OE33 were co-transfected with various combinations of pGL3 
luciferase reporter vectors. The plasmids used in the luciferase reporter assay included pGL3 
control vector, luciferase reporter vector with wild type or mutant type 3’-UTR of DKK2 and 
miR-221 mimics or negative control (Figure 5-4). Compared with wild type 3’-UTR of DKK2 
and negative control, a significantly decreased luciferase activity was observed in cells 
transfected with wild type 3’-UTR of DKK2 and miR-221 mimics. However, there was no 
difference of luciferase activity observed in cells transfected with mutant type 3’-UTR of 
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DKK2 and miR-221 mimics. These results indicated that miR-221 directly targets the 3’-UTR 
sequences of DKK2 to mediate its tumor promoting function.  
 
 
Figure 5-4. Luciferase reporter analysis. The results revealed direct binding of miR-221 to the 
wild type (WT), but not the mutant (Mut) sequences within the 3’UTR regions of DKK2. Ctrl: 
transfection of negative control; miR-221: transfection of miR-221 mimics. ***p<0.001, t-test.  
6. MiR-221 regulates Wnt/β-catenin pathway in EC cells 
As mentioned above, we have identified that DKK2 (an inhibitor of Wnt pathway) is a direct 
target of miR-221 in esophageal cancer cells. Next we investigated whether miR-221 
modulated Wnt/β-catenin pathway by targeting DKK2.  
Firstly we performed IF staining for distribution of β-catenin protein in 5-FU sensitive and 
resistant esophageal cancer cells after transfection with miR-221 mimics, miR-221 inhibitors 
and negative control siRNA. Immunofluorescence analysis revealed that β-catenin is 
expressed at cell membrane of OE33, and in cell plasma and cell nuclei of OE33-5Fures. Up-
regulation of miR-221 promoted the translocation of β-catenin into cell plasma and cell nuclei 
in OE33 cells, while down-regulation of miR-221 enhanced β-catenin returning back to cell 
membrane of OE33-5Fures cells (Figure 6-1). 
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Figure 6-1. Distribution of β-catenin in OE33 and OE33-5FUres with hsa-miR-221 mimics or 
inhibitors transfection. β-catenin is expressed at cell membrane of OE33, and in cell plasma 
and cell nuclei of OE33-5FUres. Restoration of miR-221 promoted the translocation of β-
catenin into cell plasma and cell nuclear in OE33 cells. While loss of miR-221 promoted β-
catenin returning back to the cell membrane of OE33-5FUres cells.  
In addition, we used TOP/FOP Flash luciferase reporter assay for further verification to the 
activity of β-catenin after transfection with miR-221 mimics, miR-221 inhibitors, negative 
control siRNA and positive control β-catenin siRNA (siR-β). The Western blot result in 
Figure 6-2 showed the efficacy of β-catenin siRNA, which can strongly knockdown β-catenin 
in 5-FU resistant EC cells.  
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TOP/FOP Flash luciferase reporter analysis revealed an significantly increased luciferase 
activity following transfection with miR-221 mimics and a dramatic decreased luciferase 
activity following transfection with miR-221 inhibitors or siRNA-CTNNB1(siR-β) (**p<0.01, 
Figure 6-2). These results indicated that miR-221 mediated Wnt/β-catenin pathway 
modulation in esophageal cancer cells via interaction with DKK2 mRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2. Top/Fop Flash luciferase reporter analysis. Overexpression of miR-221 in OE33 
cells increased the luciferase activity compared to the control group, while loss of miR-221 by 
its inhibitors in OE33-5FUres cells decreased the luciferase activity. Moreover, knockdown of 
β-catenin by siRNA-CTNNB1 in OE33-5FUres cells significantly inhibited the luciferase 
activity. **p<0.01, t-test. 
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7. EMT related genes are regulated by miR-221 and β-catenin in EC cells 
In this study, 5-FU resistant EC cells acquired a mesenchymal cell like phenotype as shown in 
Figure 7-1. This indicated that epithelial-mesenchymal transition (EMT) might be involved in 
the 5-FU resistance of esophageal cancer cells. Moreover, in our preliminary work, we found 
dysregulation of EMT related genes in side population cells of 5-FU sensitive and resistant 
esophageal cancer cells[31]. Therefore, here we investigated whether miR-221 regulates 
epithelial-mesenchymal transition in 5-FU resistant esophageal cancer cells.  
 
Figure 7-1. Morphology of 5-FU sensitive and resistant esophageal cancer cells. 
Mesenchymal cell- like morphology changes were observed in 5-FU resistant OE19 and OE33 
cell lines as compared with 5-FU sensitive esophageal cancer cells (red arrows).  
We analyzed the protein level of the epithelial cell marker E-cadherin and the mesenchymal 
cell marker vimentin in OE33 and OE33-5FUres cells after treatment with miR-221 mimics, 
inhibitors and siRNA-CTNNB1. Western blot analysis (Figure 7-2) revealed a dramatic 
increase of vimentin and a noticeable decrease of E-catenin in OE33-5FUres cells compared 
with OE33 cells. Overexpression of miR-221 dramatically increased vimentin expression in 
OE33 cells, while loss of miR-221 and β-catenin resulted in an increased E-cadherin and 
decreased vimentin expression in OE33-5FUres cells. These results indicated that miR-221 
could modulate the epithelial-mesenchymal transition in esophageal cancer cells.  
56 
 
 
 
Figure 7-2. Analysis of EMT related genes in 5-FU sensitive and resistant esophageal cancer 
cells. Western blot analysis showed that the epithelial cell marker E-cadherin was expressed 
at a lower level in OE33-5Fures cells as compared to the parental OE33 cells; by contrast, the 
mesenchymal cell marker vimentin was increased in the OE33-5Fures cells as compared to the 
OE33 cells. An effect of miR-221 on this process was established by knockdown of miR-221 
expression in OE33-5Fures cells which resulted in a significant increase in E-cadherin and a 
decrease in protein expression of vimentin. 
 It has been reported that the Wnt pathway can mediate tumorigenesis and chemoresisatance 
of various cancers via activation of the EMT [74,78–83]. We found Wnt pathway-mediated 5-FU 
resistance in esophageal cancer cells regulated by miR-221. To analyze this interaction we 
performed a series of assays to determine the relationship between miR-221/Wnt/β-catenin 
and EMT. 
To identify EMT associated target genes of Wnt/β-catenin in esophageal cancer cells, we 
analyzed the expression of selected β-catenin targets genes in OE33 and OE33-5FUres cells 
after transfection with miR-221 mimics, inhibitors or siRNA-CTNNB1 by using customer 
RT-PCR profiles. The overexpression or loss of miR-221 and knockdown of CTNNB1 in 
OE33-5FUres resulted in differential gene expression (Figure 7-3).  CD44, ABCG2, MYC and 
CDH1 were found to be expressed significantly different in OE33-5FUres cells versus OE33 
cells and to be regulated by miR-221 mimics, miR-221 inhibitors and siR-CTNNB1.  
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Figure 7-3. Customer RT-PCR array analysis. EMT related Wnt/β-catenin target genes are 
expressed differently in OE33 and OE33-5FUres cells after treatment with miR-221 mimics, 
inhibitors or siR-CTNNB1. The expression of seven genes in OE33 cells were increased by 
treatment with miR-221 mimics, while most of the 33 selected genes were regulated by miR-
221 inhibitors in OE33-5FUres cells. Four genes MYC, CD44, ABCG2 and CDH1 were found 
to be dysregulated between OE33 and OE33-5Fures cells, and to be influenced by miR-221 
up or down regulation. Four genes CDH1, MYC, CD44 and ABCG2 were regulated by both 
miR-221 and β-catenin. 
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Discussion 
The development of chemoresistance is one of the major challenges in the treatment of 
patients with cancer including esophageal cancer. In the present study, we focused on 
miRNAs that are known to be associated with the sensitivity to anticancer therapies. We have 
3 new findings in this study. First, in esophageal cancer, overexpression of miR-221 was 
closely associated with resistance to anticancer therapy with 5-FU. Second, miR-221 could 
regulate Wnt/β-catenin pathway by directly targeting a Wnt inhibitor DKK2. Third, miR-221 
could mediate epithelial mesenchymal transition through regulating Wnt/β-catenin pathway. 
Many miRNAs are known to be associated with chemotherapeutic efficacy. For example, it is 
reported that overexpression of miR-214 can induce cisplatin resistance by targeting PTEN in 
ovarian cancer[84] and high expression of miR-21 is involved in gemcitabine resistance in 
pancreatic cancer and chemosensitivity is regained by downregulation of miR-21  by indole-
3-carbinol[85]. On the other hand, let-7a can repress chemoresistance and tumorigenicity in 
head and neck cancer through stem-like properties ablation[86]. Low expression of miR-345, 
miR-7, miR-181a and miR-630 are associated with chemoresistance of breast, lung and 
ovarian cancer[87,88]. To our knowledge, the relationship between miR-221 expression and 
chemoresistance in cancers has not been analyzed previously. In the present study, we showed 
that miR-221 expression is significantly associated with chemosensitivity of esophageal 
cancer to 5-FU.  
The results showed that up-regulation of miR-221 is critical for 5-FU resistance and tumor 
growth of esophageal cancer cells both in vitro (Figure 3-1~Figure3-4) and in vivo (Figure 4-
1~Figure 4-3). MiR-221 is located on chromosome X and has been shown to be over 
expressed in colorectal cancer, ovarian cancer, breast cancer, osteosarcoma, and pancreas 
cancer. In colorectal cancer, miR-221 promotes cell proliferation and metastasis both in vivo 
and in vitro[89,90]. In addition, it could mediate the epithelial-mesenchymal transition in 
pancreas cancer cells[76]. Moreover, miR-221 plays an important role in mediating radio-
chemo resistance by targeting multi-pathways. MiR-221 targeting PI3K/Akt signaling axis 
induces cell proliferation and 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) resistance in 
human glioblastoma and down-regulation of miR-221 regulates radiation sensitivity by 
targeting the PTEN pathway. Overexpression of miR-221 is associated with tamoxifen 
resistance in breast cancer by negatively regulating estrogen receptor alpha[91–93]. MiR-221 
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induces cell survival and cisplatin resistance through PI3K/Akt pathway in human 
osteosarcoma and up-regulation of miR-221 can regulate gastric carcinoma cell proliferation 
and radioresistance by targeting PTEN[94,95]. MiR-221 confers breast cancer fulvestrant 
resistance by regulating multiple signaling pathways[96].  
Besides the role of miR-221 in esophageal cancer chemotherapy resistance, we identified 
DKK2 as the functional target of miR-221 regulating cell proliferation and 5-FU resistance 
(Figure 5-1~Figure 5-4). DKK2, one member of the Dickkopf protein family, is generally 
thought to be a direct inhibitor of the Wnt pathway. It can suppress the activity of Wnt 
pathway by binding to the LRP5/LRP6 co-receptors of frizzled (FZD). It is reported that 
DKK2 expression is remarkably decreased in melanoma and gastrointestinal cancer[97–99]. In 
glioma, DKK2 was identified as a direct target of miR-222[100]. MiR-221 and miR-222 belong 
to the same family and are highly similar. Here we found that miR-221 can bind the 3’UTR of 
DKK2 and inhibit the expression of DKK2 possibly at both mRNA and protein level (Figure 
5-4).  
The Wnt/β-catenin signaling pathway is the canonical Wnt pathway, which plays an 
important role in cell self- renewal, cell proliferation, cell migration and carcinogenesis as well 
as chemoresistance of cancer. It has been reported to be activated by 5-FU[101–103]. In this 
study, we found that the Wnt/β-catenin signaling pathway was activated in 5-FU resistant EC 
cells and knockdown of β-catenin could decrease the activity of the TCF/LEF transcriptional 
complex identified by TOP/FOP Flash luciferase reporter analysis (Figure 6-2). We also 
found overexpression and loss of miR-221 could regulate the activity of TCF/LEF 
transcriptional complex. We speculated that miR-221 might promote 5-FU resistance by 
regulating Wnt/β-catenin signaling pathway via DKK2. To elucidate the underlying 
mechanism, we measured the activity of the Wnt/β-catenin signaling pathway. The results 
(Figure 5-3) showed that miR-221 overexpression inhibited the expression of DKK2 proteins, 
which abrogated the inhibitory effect of DKK2 on Wnt/β-catenin signaling. This phenomenon 
then led to the disruption of the Axin/APC/GSK3 complex, thereby stabilizing β-catenin and 
permitting its subsequent activation. The activated β-catenin was then translocated into the 
nucleus, where it in turn activated its downstream effectors and functionally contributed to 
tumorigenesis. In the present study, we demonstrated for the first time that miR-221 functions 
as an oncomiR in esophageal cancer via targeting DKK2 and activating the Wnt/β-catenin 
signaling pathway.  
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In this study, the phenomenon of EMT was shown as a result of continuously exposing 
esophageal cancer cell lines to 5-FU (Figure 7-1) and EMT related markers E-cadherin and 
vimentin were expressed differently between 5-FU sensitive and resistant EC cells (Figure 7-
2). It was reported before that EMT is closely associated with the resistance of cancer to 
chemotherapy. In MCF-7 breast cancer cells, Zhang W et al found that chemoresistance of 5-
FU induces epithelial-mesenchymal transition via up-regulation of Snail [104].  Arumugam T et 
al found that epithelial-mesenchymal transition contributes to drug resistance in pancreatic 
cancer[105]. Findlay VJ et al found that Snail2 modulates colorectal cancer 5-FU sensitivity[106]. 
In addition, EMT is reported to be regulated by the Wnt/β-caternin signaling pathway[79,107,108]. 
We hypothesized that miR-221 induced 5-FU resistance through the cross talk between 
Wnt/β-catenin pathway and EMT in esophageal cancer. To elucidate this hypothesis, we 
analyzed the Wnt/β-catenin pathway genes, which also might be related with EMT. We found 
that MYC, CD44, CDH1 and ABCG2 were expressed differently between 5-FU sensitive and 
resistant EC cells and were regulated by miR-221 (Figure 7-3). This is the first report to 
connect the Wnt/β-catenin pathway and EMT in 5-FU resistance of esophageal cancer.  
Chemoresistance is a major issue of treatment in the majority of human tumors, including 
esophageal cancer. Thus, detecting rationale biomarkers to predict chemotherapy sensitivity 
and screening for targets to overcome resistance are significant for cancer therapy. A specific 
miRNA can affect simultaneously the expression of proteins involved in multiple cellular 
pathways, potentially serving as better therapeutic target or biomarker for clinical outcome 
than single proteins. In fact, several miRNAs, including miR-21, miR-200c and miR-125b, 
have been used as predictors of chemoresistance in cancers[62,68,109]. Herein, our observation 
that increased miR-221 expression is associated with chemotherapy resistance, and poor 
patient prognosis may provide a surrogate marker to predict chemotherapeutic sensitivity for 
esophageal cancer.  
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Summary
 
  
Figure XIV. Summary of this study. In conclusion, our results propose miR-221 as a promoter 
of 5-FU resistance of esophageal cancer. We defined a signaling axis of miR-221-DKK2-
Wnt/β-catenin-EMT in esophageal cancer. In esophageal cancer cells, miR-221 activates the 
Wnt/β-catenin pathway by directly targeting DKK2 (an inhibitor of the Wnt/β-catenin 
pathway), which might promote cell proliferation. The activation of the Wnt/β-catenin 
pathway leads to accumulation of TS (a 5-FU target and resistance marker) and epithelial-
mesenchymal transition by regulating its downstream targets (c-myc, E-cadherin, CD44 and 
ABCG2), which might induce 5-FU resistance of esophageal cancer cells.    
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Zusammenfassung 
Einleitung 
Das Ösophaguskarzinom ist der achthäufigste Krebs und die sechsthäufigste krebsbedingte 
Todesursache. Chemotherapie-Resistenz stellt in der Behandlung des Ösophaguskarzinoms 
ein sehr großes Problem dar. Es haben sich zunehmend mehr Hinweise in der Literatur 
ergeben, dass microRNAs (miRNAs) eine wichtige Rolle bei der Tumorentstehung und 
Chemotherapie-Resistenz verschiedener Tumorerkrankungen spielen. Es ist jedoch nicht 
bekannt, wie miRNAs Chemotherapie-Resistenz  beim Ösophaguskarzinom regulieren. Ziel 
dieser Arbeit war es, zu analysieren inwieweit beim Ösopahguskarzinom miRNAs 
Chemotherapie-Resistenz und damit möglicherweise gesteigerte Metastasierungsfähigkeit 
regulieren. 
Methodik 
Für diese Studie wurden zuerst 5-FU-resistente Zelllinien aus vier verschiedenen 
Ösophaguskarzinimzelllinien hergestellt. Anschließend wurde das miRNA-Profil in 5-FU 
resistenten Ösophaguskarzinomzelllinien sowie den ursprünglichen sensitiven 
Tumorzelllinien mittels qPCR erfasst. Nach Transfektion von miR-221, Antagomirs als 
Inhibitoren von miR221 (anti221) oder entsprechenden Negativkontrollen (antiCtrl oder 
siRCtrl) in resistente sowie sensitive Ösophaguskarzinomzelllinien erfolgten sowohl In-vitro- 
als auch In-vivo-Experimente zur Analyse der zell- und molekularbiologischen 
Veränderungen. In vitro wurden die Zell-Proliferation und Zytotoxizität der 
Ösophaguskarzinomzelllinien gegenüber 5-FU durch CCK-8 untersucht. In vivo wurden 
OE33 und OE33-5FUres Zellen subkutan in Nacktmäusen implantiert und die Tumorgröße 
gemessen. Ki67-und CD31-Expression zur Bewertung der Proliferation und Angiogenese in 
Tumoren wurde durch immunhistochemisch Färbung (IHC) und Immunfluoreszenz (IF) 
analysiert. Zur weiteren Untersuchung der molekularen Mechanismen von miR-221 auf 5-
FU-Behandlung von Ösophagsukarzinomzellen, wurden miR-221-Zielgene bioinformatisch 
detektiert und durch qPCR und Western-Blot analysiert. Die  Identifizierung der Interaktion 
von miR-221 und DKK2 erfolgte durch Luciferase-Reporter-Assays mittels Luciferase-
Reporter-Vektorkonstrukten pGL3-DKK2-wt und pGL3-DKK2-mut (mit Wildtyp oder 
mutierter 3'-UTR-Sequenz). Die Lokalisation von β-Catenin und die Aktivität des WNT/β-
Catenin-Signalwegs wurden durch Immuncytofluoreszenz-Färbung (IF) und TOP/FOP Flash-
Reporter-Assays beurteilt. Zur Analyse einer eher mesenchymalen Zellmorphologie von 5-
63 
FUres-Ösopaguskarzinomzellen wurden EMT-Marker E-Cadherin und Vimentin durch qPCR 
und Western-Blot nachgewiesen. EMT-assoziierte relevante WNT/β-Catenin-Zielgene 
wurden mittels der “Customized Array”-Technologie analysiert.  
Ergebnisse 
In dieser Studie war miR-221 deutlich in allen 5-FUres-Ösophaguskarzinomzelllinien im 
Vergleich zu den jeweiligen sensitiven Zellen hochreguliert. In vitro-Knockdown von miR-
221 führte zur Reduktion der Zellproliferation und sensibilisierte die 
Ösophaguskarzinomzellen gegenüber 5-FU bei 2.5 μg/ml und 20 μg/ml. In vivo führt eine 
miR-221-Inhibition zu deutlich geringerem Tumorwachstum subkutan in BALB/c nu-nu 
Mäusen und inhibiert Tumorangiogenese. 120 gemeinsame Gene in vier microRNA-
Zieldatenbanken wurden als Kandidatengenen von miR-221 vorhergesagt. Wir konzentrierten 
uns auf DKK2, einem Antagonisten des Wnt/β-Catenin-Signalwegs. Die mRNA und 
Proteinexpression von DKK2 war umgekehrt proportional zur miR-221-Expression in 5-FUres 
Ösophaguskarzinomzellen exprimiert. Luciferase-Reporter-Analysen ergaben, dass DKK2 ein 
direktes Zielgen von miR-221 in Ösophaguskarzinomzellen ist. Nach Transfektion von miR-
221-Inhibitoren in 5-FUres-Ösophaguskarzinomzellen, war β-Cateninlokalisation im 
Zytoplasma und an der Zellmembran. Durch Immunfluoreszenz-cytochemische-Färbungen 
zeigte sich, dass β-Catenin in der Zellmembran und im Zytoplasma von sensitiven 
Ösophaguskarzinomzellen lokalisiert ist, während in 5-FUres-Ösophaguskarzinomzellen β-
Catenin in den Zellkern transloziert war. Darüber hinaus zeigten TOP/FOP-Flash-Reporter-
Analysen eine dramatische Abnahme der Luciferase-Aktivität von β-Catenin-siRNA und 
miR-221-Hemmern. Diese Ergebnisse zeigten, dass der Wnt/β-Catenin-Signalweg durch β-
Catenin-siRNA und miR-221-Inhibitoren inaktiviert war. 5-FUres Ösophaguskarzinomzellen 
weisen eine mesenchymale Zellmorphologie auf mit aktivierter EMT. Einige EMT relevante 
WNT/β-Catenin-Zielgene MYC, CDH1 und CD44 sowie der Chemotherapie-Resistenz-
Marker ABCG2 wurden in 5-FUres -Ösophaguskarzinomzellen durch miR-221 reguliert.  
Schlussfolgerung 
miR-221 spielt eine wichtige Rolle bei der Chemotherapie-Resistenz beim 
Ösophaguskarzinom und moduliert über den Wnt-Signalweg EMT. miR-221 könnte einen 
Prognosemarker und therapeutisches Ziel für Patienten mit 5-FUres Ösophaguskarzinom 
darstellen. 
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Abbreviation 
3’-UTR, the three prime untranslated region  
5-FU, fluorouracil 
5-FUres, 5-FU resistant esophageal cancer cells  
ABC, avidin biotin complex 
Anti-221, Hsa-miR-221 inhibitor 
BALB/C nu/nu, bagg-albino/c nude/nude 
BCNU, 1,3-bis-(2-chloroethyl)-1-nitrosourea 
BE, Barrett’s esophagus.  
CCK-8, cell counting kit-8 
CD, cluster of differentiation 
CDK, cyclin-dependent kinase 
cDNA, complementary deoxyribonucleic acid 
CT, cycle threshold 
DAPI, 4’, 6-Diamidin-2-phenyl- indol 
DMEM, dulbecco's modified eagle medium 
DMSO, dimethyl sulfoxide  
DNA, desoxyribonucleic acid 
FACS, fluorescence activated cell scan 
FCS, fetal calf serum 
FZD, frizzled 
EC, esophageal cancer 
EAC, esophageal adenocarcinoma 
EGF, epithelial growth factor 
EMT, epithelial to mesenchymal transition 
ESCC, esophageal squamous cell carcinoma 
FGF, fibroblast growth factor 
HE, hematoxylin and eosin 
HLA-DR, human leukocyte antigens-DR (major histocompatibility complex, MHC class II) 
HRP, horseradish peroxidase 
IC50, the half maximal inhibitory concentration 
IHC, immunohistochemistry 
IF, immunocytofluorescence 
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miRNA, micro ribonucleic acid 
siRCtrl, negative control siRNA 
Mut, luciferase repoter vector with mutant 3’-UTR of DKK2 
PECAM-1, platelet-endothelial-cell-adhesion-molecule-1 (CD31) 
PT, PT1590 cell line 
qRT-PCR,  real time quantitative reverse transcriptase polymerase chain reaction 
LN, LN1590 cell lines 
MDR, multidrug resistance gene 1 
RNA, ribonucleic acid 
RT-PCR, reverse transcriptase polymerase chain reaction 
s.c., subcutaneous 
siRCtrl, miRNA inhibitor negative control  
siR-β, β-catenin siRNA  
TS, thymidylate synthase 
SP, side population 
VEGF, vascular endothelial growth factor 
Wnt, wingless-type MMTV integration site family 
WT, luciferase reporter vector with wild type 3’-UTR of DKK2 
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